The aim of the present study was to improve the performance of pyrosequencing assay for EGFR mutation detection by setting up a novel dispensation order (NDO) capable not only to detect but also to characterize the type of mutations of exon 19 associated to the responsiveness to TKI therapy[14], and to validate its efficacy in the clinical setting in a consecutive prospectively collected series of lung cancer specimens. This evidence concerns the gene EGFR and lung cancer.